Intellia Therapeutics' stock surged 5.02% during Thursday's intraday trading session.
The significant price increase appears to be driven by news that Cathie Wood's ARK Investment purchased 2.4 million shares of the gene-editing company. Such a substantial acquisition by a prominent institutional investor typically signals strong confidence in the company's prospects and generates positive market sentiment.